1. 1245PDIntratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study. (23rd October 2018) Authors: Diab, A; Haymaker, C; Bernatchez, C; Andtbacka, R H I; Shaheen, M; Johnson, D; Markowitz, J; Puzanov, I; Murthy, R; Johnson, D H; James, M; Chunduru, S; Geib, J; Swann, S; Rahimian, S; Hwu, P Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LBA49Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC). (23rd October 2018) Authors: Cascone, T; William, W N; Weissferdt, A; Leung, C H; Federico, L; Haymaker, C; Bernatchez, C; Fossella, F V; Mott, F E; Papadimitrakopoulou, V A; Byers, L; Lam, V K; Godoy, M C; Carter, B; Lee, J J; Vaporciyan, A; Gibbons, D L; Swisher, S G; Heymach, J V; Sepesi, B Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗